Locations
San Carlos, CA, USA · San Francisco, CA, USA
industry
Biotechnology · DeepTech · Health
Size
51-200 employees
Stage
Series B
founded in
2017
Elegen is a biotechnology company specializing in innovative cell-free DNA synthesis technology, offering ENFINIA DNA, which provides rapid, high-accuracy, long, and complex linear DNA synthesis. Their proprietary technology allows for the production of DNA up to 7 kb in length with an error rate as low as 1:70,000 bp, significantly streamlining workflows in synthetic biology and gene therapy. Elegen's products are designed to eliminate the need for cloning, saving time and costs in various applications, including mRNA vaccine development and biomanufacturing. With a recent $35 million Series B funding round, Elegen is positioned for growth in clinical manufacturing and aims to advance the bioeconomy through innovative DNA manufacturing processes.
Something looks off?On-site & Remote